Advertisement
Advertisement
NTLA
Intellia Therapeutics, Inc
13.16
USDSponsored
-0.57
-4.17%
Jun 02, 13:54 UTC -4
Open
NTLA Earnings Reports
Positive Surprise Ratio
NTLA beat 23 of 41 last estimates.
56%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$14.27M
/-$0.84
Implied change from Q1 26 (Revenue/ EPS)
-5.15%
/+3.70%
Implied change from Q2 25 (Revenue/ EPS)
+0.19%
/-14.29%
Intellia Therapeutics, Inc earnings per share and revenue
On May 11, 2026, NTLA reported earnings of -0.81 USD per share (EPS) for Q1 26, beating the estimate of -0.93 USD, resulting in a 13.10% surprise. Revenue reached 15.05 million, compared to an expected 15.09 million, with a -0.27% difference. The market reacted with a +2.34% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.84 USD, with revenue projected to reach 14.27 million USD, implying an increase of 3.70% EPS, and decrease of -5.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Greenwich LifeSciences, Inc.
Report Date
Jun 01, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.57
Surprise
-77.70%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Intellia Therapeutics, Inc reported EPS of -$0.81, beating estimates by 13.1%, and revenue of $15.05M, -0.27% below expectations.
How did the market react to Intellia Therapeutics, Inc's Q1 2026 earnings?
The stock price moved up 2.34%, changed from $14.09 before the earnings release to $14.42 the day after.
When is Intellia Therapeutics, Inc expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Intellia Therapeutics, Inc's next earnings report?
Based on 13
analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.84 and revenue of $14.27M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement